Synthetic proteins for COVID-19 diagnostics

Catherine H. Schein, Corri B. Levine, Susan McLellan, Surendra S. Negi, Werner Braun, Stephen C. Dreskin, Elizabeth S. Anaya, Jurgen Schmidt

Research output: Contribution to journalArticlepeer-review

Abstract

There is an urgent need for inexpensive, rapid and specific antigen-based assays to test for vaccine efficacy and detect infection with SARS-CoV-2 and its variants. We have identified a small, synthetic protein (JS7), representing a region of maximum variability within the receptor binding domain (RBD), which binds antibodies in sera from nine patients with PCR-verified COVID-19 of varying severity. Antibodies binding to either JS7 or the SARS-CoV-2 recombinant RBD, as well as those that disrupt binding between a fragment of the ACE2 receptor and the RBD, are proportional to disease severity and clinical outcome. Binding to JS7 was inhibited by linear peptides from the RBD interface with ACE2. Variants of JS7, such as E484K or N501Y, can be quickly synthesized in pure form in large quantities by automated methods. JS7 and related synthetic antigens can provide a basis for specific diagnostics for SARS-CoV-2 infections.

Original languageEnglish (US)
Article number170583
JournalPeptides
Volume143
DOIs
StatePublished - Sep 2021

Keywords

  • ACE2 interaction
  • COVID-19 variants
  • Neutralizing antibodies
  • Peptide vaccines
  • Receptor binding domain
  • S protein epitopes
  • Structure based design

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Endocrinology
  • Cellular and Molecular Neuroscience

Fingerprint

Dive into the research topics of 'Synthetic proteins for COVID-19 diagnostics'. Together they form a unique fingerprint.

Cite this